Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 4Carcinoma, Medullary 4Carcinoma, Non-Small-Cell Lung 3Wilms Tumor 2Thyroid Diseases 2Thyroid Cancer, Papillary 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Thyroid Carcinoma, Anaplastic 1Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Neoplasms by Site 1Neoplasms 1Lymphoma 1Lung Diseases 1

Interventions

Nivolumab 2trametinib 1selpercatinib 1lenvatinib 1fludarabine 1dabrafenib 1cemiplimab 1aldesleukin 1Radiotherapy, Intensity-Modulated 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × selpercatinib × 90 days × Clear all
NCT04759911 2026-05-20

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡